Business Wire

CYBERSECURITY-TECH-ACCRD

22.2.2021 12:02:08 CET | Business Wire | Press release

Share
State-Sponsored Cyberattacks: A Major Threat to Businesses, Study Finds

A majority of businesses surveyed for a study by the Economist Intelligence Unit (EIU) and the Cybersecurity Tech Accord released today, see state-led and sponsored cyberattacks as a major threat. They are concerned about catastrophic reputational and financial consequences and call for greater international political cooperation to mitigate these threats.

The survey was conducted between November and December 2020, before the pernicious cyberattack on software company SolarWinds came to light. That attack was a moment of reckoning for many organizations about the challenges posed by state-led and -sponsored cyberattacks but, as the survey reveals, many businesses have long been aware of the escalating threat.

In recent years, cyberattacks led or sponsored by states have transformed cyberspace. This escalating conflict online has been accelerated by the wide-reaching consequences of COVID-19. In fact, almost 8-in-10 respondents say the pandemic has increased the likelihood of a state-led or -sponsored cyberattack on their organization.

Results show private sector leaders expect cyber threats by state actors to increase in the years ahead and want governments to implement effective policy solutions at the national and international level. In further detail, the key study findings are:

  • State-led and -sponsored cyberattacks are a source of major concern for private organizations . 80 percent of respondents are concerned about their organization falling victim to a nation-state cyberattack, with the majority saying that this concern has increased in the past five years.
  • Companies expect cyber threats from nation-state actors to increase in the next five years and will be second only to that of organized crime. This would be a grave development, given that states have significant resources and advanced tools and technologies, which can later be repurposed by other attackers.
  • There is a false sense of security. 68 percent of executives feel their organizations are “very” or “completely” prepared to deal with a cyberattack. Charles Carmakal, senior vice president and chief technology officer at FireEye and one of the experts interviewed by the EIU, suggested that most organizations don’t have tangible experience dealing with such threats because they are rarely the primary targets of these attacks. The recent SolarWinds hack may compel more organizations to think about how they mitigate risk.
  • Increased corporate investment in cybersecurity is crucial but government action, nationally and internationally, is needed . 6-in-10 executives say that their country only offers a medium or low level of protection and that stronger international economic and political cooperation is essential to address the challenges, and to cultivate a more secure and stable online environment.

“Recent state-led and -sponsored attacks serve as a powerful reminder of an escalating problem that is too big to ignore,” said Brad Maiorino, executive vice president and chief strategy officer, FireEye. “There needs to be a fundamental shift in security planning beyond the efforts of any one organization, and this shift requires proactive and cooperative action from government and industry.”

“Although cyberattacks are a silent threat, they can have devastating and long-lasting effects on our society. Given the recent escalation of tensions in cyberspace, cooperation between governments is becoming increasingly complicated as political systems differ and technological competition rises,” said Marietje Schaake, president of the CyberPeace Institute. "This survey is an important call to action for democratic governments to step up and think more inclusively about the kind of cyber assistance they provide to protect companies in key sectors, and ultimately civilians."

Since its inception, the Cybersecurity Tech Accord has highlighted this troubling situation, inviting governments to protect the online environment and refrain from using the internet as a domain of conflict, directly or through third parties. As an industry voice and staunch advocate for responsible behavior in cyberspace, the Cybersecurity Tech Accord has consistently called on governments to do more to defend against cyber-threats online, uphold international law, and implement international cybersecurity norms.

“As a coalition of over 150 global technology companies, we are greatly concerned by state-sponsored cyberattacks, which are becoming ever more frequent and sophisticated. Something needs to be done and soon,” said Annalaura Gallo, secretariat of Cybersecurity Tech Accord. “This survey shows that businesses see state-led and -sponsored cyberattacks as a pressing issue that demands governments act nationally and internationally. We need agreement at the United Nations and the involvement of business and civil society through multi-stakeholder forums, such as the Paris Call for Trust and Security in Cyberspace. We hope these survey results will be the start of a larger, global conversation around this important topic.”

The survey targeted over 500 director-level or above executives from businesses in Asia-Pacific, Europe, and the United States, familiar with their organization’s cybersecurity strategy and representing a wide range of industries, led by IT and technology, retail and consumer goods.

For a summary of key takeaways from the report, see the infographic here , and for full details, click here .

To learn more about the Cybersecurity Tech Accord, visit www.cybertechaccord.org .

About the Cybersecurity Tech Accord: In April 2018, 34 global technology and security companies signed the Cybersecurity Tech Accord, a watershed agreement and public commitment to protect and empower civilians online. Since then, this initiative has become the largest industry-led effort of its kind, with over 150 signatory companies across the world pledging to improve the security, stability, and resilience of cyberspace. More information can be found here .

About the Economist Intelligence Unit (EIU): The EIU is the thought leadership, research and analysis division of The Economist Group and the world leader in global business intelligence for executives. The EIU uncovers novel and forward-looking perspectives with access to over 650 expert analysts and editors across 200 countries worldwide. More information can be found here .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye